Role of molecular imaging in the detection of neuroendocrine tumour
- Damian Wild1
© Wild; licensee BioMed Central Ltd. 2014
Published: 9 October 2014
Neuroendocrine tumours (NETs) have distinct biological and clinical characteristics, in particular a high density of somatostatin receptors at the cell membrane . It is this property that allows the use of radiolabelled somatostatin analogues for imaging of these tumours. Importantly, somatostatin receptor PET/CT imaging (e.g. 68Ga-DOTATOC, 68Ga-DOTATATE, 68Ga-DOTANOC) is superior to somatostatin receptor scintigraphy including SPECT/CT  and 18F-DOPA PET/CT  in the detection of gastroenteropancreatic neuroendocrine tumours (GEP NETs).
NETs, however, have a wide range of cellular differentiation. 18F-FDG PET/CT is of limited value in well-differentiated NETs but of high value in poorly differentiated NETs. Somatostatin receptor PET/CT shows contrary results . As both 18F-FDG PET/CT and somatostatin receptor PET/CT exploit distinct tumour characteristics they are complementary for tumour staging.
Small insulinomas are difficult to detect with 18F-FDG PET/CT, somatostatin receptor PET/CT, 18F-DOPA PET/CT and morphological imaging. Targeting of Glucagon-like peptide-1 receptors using radiolabelled exendin-4 has shown to be highly effective in the detection of these tumours .
Clinical studies have shown higher tumour uptake of radiolabelled somatostatin receptor antagonists than somatostatin receptor agonists . As a result radiolabelled somatostatin receptor antagonists may have a significant impact on imaging of NETs.
- Reubi JC, Waser B: Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003, 30: 781–793. 10.1007/s00259-003-1184-3PubMedView ArticleGoogle Scholar
- Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V: Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012, 42: 80–87. 10.1007/s12020-012-9631-1PubMedView ArticleGoogle Scholar
- Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al.: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008, 35: 1431–1438. 10.1007/s00259-008-0769-2PubMedView ArticleGoogle Scholar
- Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al.: Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008, 112: 2447–2455. 10.1002/cncr.23469PubMedView ArticleGoogle Scholar
- Christ E, Wild D, Ederer S, Behe M, Nicolas G, Caplin ME, et al.: Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol 2013, 1: 115–122. 10.1016/S2213-8587(13)70049-4PubMedView ArticleGoogle Scholar
- Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, et al.: First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med 2011,52(1412):1417. 10.2967/jnumed.111.088922Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.